Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind upadacitinib vs placebo in RA patients with inadequate response or intolerance to biologic DMARDs
2015-003335-35Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Upadacitinib + stable csDMARDs with Placebo + stable csDMARDs (2 arms). Started Mar 2016; status: completed.
02
Drugs
upadacitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2015-003335-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003335-35.